search_response="1. Apnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug - MedCity News\nURL: https://medcitynews.com/2026/08/apnimed-ipo-apmd-obstructive-sleep-apnea-osa-oxnimbi-atomoxetine-aroxybutynin/\nDate: 2026-08-02T22:41:38.000Z\nHighlights: Apnimed, a sleep disorders drug developer whose lead therapeutic candidate is under FDA review, raised $192 million in a stock market debut that will support commercialization plans for its pill to treat obstructive sleep ap

{ "id": "b0ca480e-0975-421c-b086-ab0c36098aa6", "results": [ { "date": "2026-07-31", "last_updated": "2026-08-02", "snippet": "", "title": "Health & Pharma News | Latest Healthcare Stories | Reuters", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/" }, { "date": "2026-07-31", "last_updated": "2026-07-18", "snippet": "Please refer to\u00a0Drugs@FDA for the latest approvals and prescribing information for specific

{ "id": "d76e67ac-5e2f-4d2b-8d25-15059d8ae691", "results": [ { "date": "2026-07-30", "last_updated": "2026-08-01", "snippet": "", "title": "Pharma", "url": "https://medicalupdateonline.com/pharma/" }, { "date": "2026-07-31", "last_updated": "2026-07-18", "snippet": "Please refer to\u00a0Drugs@FDA for the latest approvals and prescribing information for specific products.\n|Webpage|Description|Date|\n...\n|FDA approves capivasertib w

VectorBio Therapeutics, a developer of next-generation viral vector delivery platforms, announced the successful closing of a $115 million Series B financing round.

Vertex Pharmaceuticals completed its acquisition of Alpine Immune Sciences for approximately $4.9 billion in cash, bolstering its portfolio in inflammatory and autoimmune diseases.

The FDA granted accelerated approval for the combination of Lumakras (sotorasib) and Vectibix (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer.

{ "id": "11c5258a-8170-4957-bec8-2cfd677d6470", "results": [ { "date": "2026-07-27", "last_updated": "2026-07-31", "snippet": "Vertex Announces US FDA Approval for Expanded Use of CASGEVY\u00ae for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia\n...\nFDA Grants Priority Review To Genentech\u2019s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (T

Neuvo-Cen failed to meet the primary endpoint in the Phase 3 'CLARITY-AD2' study regarding cognitive decline improvement.

search_response="1. FDA Approves Otsuka SIMTRIYO, First NDSRI for ADHD\nURL: https://novapharmanews.com/us/news/fda-approves-otsuka-simtriyo-centanafadine-adhd\nDate: 2026-08-01T11:34:05.000Z\nHighlights: FDA Approves Otsuka SIMTRIYO, First NDSRI for ADHD ... On July 24, 2026, FDA approved Otsuka's SIMTRIYO (centanafadine) once-daily extended-release capsule for ADHD in adults and pediatric patients aged 6 years and older weighing at least 20 kg. ... FDA approves SIMTRIYO centanafadine ADHD trea

{ "id": "b77d27b6-9f75-4e62-8050-0c0c2ed0e98d", "results": [ { "date": "2025-07-18", "last_updated": "2026-07-31", "snippet": "FDA Drug Approval Calendar MarketBeat's FDA Calendar tracks confirmed drug approvals, clinical trial results, regulatory decisions, and biotech catalysts \u2014 updated daily with real-time stock data.\nReview recent FDA actions including New Drug Application (NDA) approvals, Biologics License Application (BLA) decisions, Complete Response Lette

NeuroVance reported topline results for NV-202, an oral cognitive enhancer targeting early-stage Alzheimer's disease.

BioGenix announced a definitive agreement to acquire NephroCore Therapeutics for $1.2 billion in cash to bolster its renal pipeline.

search_response='1. Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - BioSpace\nURL: https://www.biospace.com/press-releases/johnson-johnson-completes-acquisition-of-firefly-bio-inc-to-advance-next-generation-oncology-innovation\nDate: 2026-07-30T03:35:41.000Z\nHighlights: Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation - BioSpace ... July 29, 2026 | ... NEW BRUNSWICK, N.J.--(B

{ "id": "ab924428-13d1-4988-8cf1-e5d1c3162b43", "results": [ { "date": "2026-07-26", "last_updated": "2026-07-21", "snippet": "All FDA decisions, clinical trial readouts, and key events happening this week.\n54\nTotal Events\n5\nPDUFA Dates\n52\nTrial Readouts\n...\nHELPEarnings$242M", "title": "Biotech Catalysts This Week (Jul 20 - Jul 26, 2026 ...", "url": "https://catalystalert.io/this-week" }, { "date": "2026-07-30", "last_updated": "

Altis Therapeutics reported topline results from the Phase 2b 'CLEAR-PS' study evaluating AT-887, an oral JAK1/TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis.

On July 9, 2026, the FDA approved isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications.

On July 14, 2026, the FDA granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged two years and older with locally advanced or metastatic solid tumors with a RET gene fusion.

On July 16, 2026, Angelini Pharma announced the completion of its acquisition of Catalyst Pharmaceuticals, expanding its presence in the U.S. market and strengthening its portfolio in brain health and rare diseases.

On July 6, 2026, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion.

On July 17, 2026, the FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia.

search_response='1. FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol\nURL: https://jamanetwork.com/journals/jama/fullarticle/2852500\nDate: 2026-07-31T17:28:56.000Z\nHighlights: # FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol ... Published: 2026-07-31T17:28:56+00:00 ... The US Food and Drug Administration (FDA) approved the first oral protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to reduce low-density lipoprotein (LDL) cholesterol. PCSK9 inhibito

{ "id": "a1a58b4e-dcbf-42fa-8903-995b138af456", "results": [ { "date": "2026-07-26", "last_updated": "2026-07-21", "snippet": "All FDA decisions, clinical trial readouts, and key events happening this week.\n54\nTotal Events\n5\nPDUFA Dates\n52\nTrial Readouts\n...\nHELPEarnings$242M", "title": "Biotech Catalysts This Week (Jul 20 - Jul 26, 2026 ...", "url": "https://catalystalert.io/this-week" }, { "date": "2026-07-30", "last_updated": "

NexaGen Therapeutics secured $115 million in Series B financing to accelerate its gene-editing platform for rare neuromuscular disorders.

BioNtech released interim results from its Phase 3 trial evaluating BNT122 as an adjuvant treatment for pancreatic ductal adenocarcinoma.